Shares of Denmark's Zealand Pharma rose 35% on Monday after results showed success in its liver disease treatment survodutide, which is also on trial as a drug to treat obesity.
The Phase 2 trial of the survodutide drug showed 83% of adults saw positive results for a form of liver inflammation caused by excess fat cells known as "MASH," the company said in an announcement Monday. Analysts latched onto the drug's possible efficacity in obesity research after the latest test results, which indicated the safety of the top dosage used in that trial.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: